Abingworth is a transatlantic bioscience investment firm founded in 1973, dedicated to investing in life sciences and healthcare companies across the US and Europe. The firm provides capital and expertise from seed through development stage, including venture and clinical co-development strategies.
67% of their portfolio is in Biotech & Life Sciences. Deal activity increased 67% year-over-year (5 deals in the last 12 months). Their most common stage is series-a (44% of deals). Average disclosed round size is $101.7M (across 40 rounds with reported amounts).
Portfolio
39
Fund Size
$465M
Top Stage
Series A
Last 12 Mo
7
Team
Kurt von Emster
Managing Partner
Andrew Sinclair
Managing Director, Head of Publics & Late Stage
Jayson Punwani
Managing Director, Head of Venture
Robert DeBenedetto
Managing Director, CCD
Travis Wilson
Managing Director, CCD
Carlos Paya
Venture Partner
Natalie Mount
Venture Partner
Scott Brun
Venture Partner
Tim Haines
Executive Partner
Vincent Miles
Executive Director
Diya Malhotra
Principal
Graham Mills
Principal
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 cAMPfield Therapeutics | Series A | $180M | Jun 2026 |
 Cytospire Therapeutics | Series A | — | May 2026 |
 R1 Therapeutics | Series A | $77.5M | Mar 2026 |
| Cytospire Therapeutics | Series A | $61M | Jan 2026 |
 Solve Therapeutics | Unknown | $120M | Jan 2026 |
 Addition Therapeutics | Unknown | $100M | Dec 2025 |
| Solve Therapeutics | Series D | $120M | Nov 2025 |
 Atsena Therapeutics | Series C | $150M | Apr 2025 |
 Timberlyne Therapeutics | Series A | $180M | Jan 2025 |
 Glycomine, Inc. | Series C | $115M | Jan 2025 |
| Atsena Therapeutics | Series C | $150M | Jan 2025 |
 Myricx Bio | Series A | $90M | Jul 2024 |
| AAscend Gene & Cell Therapies | Series A | $132.5M | May 2023 |
| AAscend Advanced Therapies | Series A | $132.5M | Mar 2023 |
 Pathalys | Growth | $150M | Jan 2023 |
 Entact Bio | Series A | $81M | Dec 2022 |
 HilleVax | Unknown | $135M | Sep 2021 |
| HHillevax, Inc. | Unknown | $135M | Sep 2021 |
 Scorpion Therapeutics | Series A | $102M | Jan 2021 |
| Atsena Therapeutics | Series A | $55M | Dec 2020 |
 Q32 Bio | Unknown | $60M | Oct 2020 |
 Spruce Biosciences | Series B | $88M | Feb 2020 |
 Spruce Biosciences, Inc. | Series B | $88M | Feb 2020 |
| Q32 Bio | Series A | $46M | Jan 2020 |
 Verona Pharma | Unknown | $200M | Jan 2020 |
Top Co-Investors
Last updated: 8 September 2026